Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)-Reference-Cited by-同舟云学术

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)

Published:2010-05 Issue:3 Volume:149 Page:376-382
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Amadori Sergio,Suciu Stefan,Selleslag Dominik,Stasi Roberto,Alimena Giuliana,Baila Liliana,Rizzoli Vittorio,Borlenghi Erika,Gaidano Gianluca,Magro Domenico,Torelli Giuseppe,Muus Petra,Venditti Adriano,Cacciola Emma,Lauria Francesco,Vignetti Marco,de Witte Theo

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2010.08095.x/fullpdf

Reference17 articles.

1. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell’Adulto Leukemia Groups;Amadori;Leukemia,2005

2. Age and acute myeloid leukemia;Appelbaum;Blood,2006

3. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment;Burnett;Cancer,2007

4. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells;van Der Velden;Blood,2001

5. Advances in the management of AML in the elderly;Estey;Clinical Advances in Hematology and Oncology,2007

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can we do better with Mylotarg? Model-based assessment of opportunities to improve therapeutic index;Toxicology and Applied Pharmacology;2024-09

2. Treatment of Acute Myeloid Leukemia in Older Adults;Cancers;2023-11-14

3. Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future;Acta Haematologica;2023

4. Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials;Expert Opinion on Emerging Drugs;2022-04-03

5. Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis;Hematology;2022-02-27